4.3 Review

Psychopharmacology of the endocannabinoids: far beyond anandamide

Journal

JOURNAL OF PSYCHOPHARMACOLOGY
Volume 26, Issue 1, Pages 7-22

Publisher

SAGE PUBLICATIONS LTD
DOI: 10.1177/0269881111405357

Keywords

2-arachidonoyl-glycerol; allosterism; anandamide; cannabis; cannabinoid; CB1; CB2; endocannabinoid; functional selectivity; GPR55; N-arachidonoyl-dopamine; N-arachidonoyl-glycine; noladin; receptor trafficking; TRPV1; virodamine

Funding

  1. CNPq CAPES
  2. Fundacao de Apoio a Pesquisa do Estado de Santa Catarina (FAPESC)
  3. CNPq

Ask authors/readers for more resources

The study of endocannabinoid pharmacology has proceeded from the discovery of Delta 9-tetrahydrocannabinol, the main psychoactive compound in Cannabis sativa, to the identification of an endogenous endocannabinoid system that is essential for physiological modulation of neuronal functions. We have not yet achieved a complete understanding of the various roles of the endocannabinoids, but this is one of the fastest-growing fields in psychopharmacology. This review starts with a brief historical description of the discovery of the endocannabinoids and then focuses on recent pharmacological advances and recently discovered endocannabinoid mechanisms of action (e.g. functional selectivity, allosterism, and receptor trafficking). Finally, we will discuss the contention that the existence of evidence-based therapeutic applications for cannabinoids and the wide range of physiological functions affected by endocannabinoids suggests that the careful study of the endocannabinoid system may lead to the development of novel therapeutic drugs with higher societal acceptability and lower side effects profiles.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available